Clinical Research Studies

Below you will find clinical research studies we are currently involved with. Click the plus ‘+’ icon to the right for further details on any particular study.

Ischemic Stroke Study:
Patients who have had a recent stroke that affects the function of either upper limb may consider being evaluated for possible enrollment into this clinical trial. The clinical trial will be evaluating a medication that is thought to improve mobility and function of the affected limb while on study medication and undergoing therapy.

Ischemic Stroke Study: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 21-Day Treatment Study, Including fMRI Sub-Study to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke Primary Outcome Measures:


Primary Outcome Measures:

  • Fugl-Meyer Assessment of Upper Extremity, Part A-D
  • Index Finger-Tapping Frequency Test
  • Nine-Hole Peg Test
  • Hand Grip Strength Dynamometer Test
  • Arm Motor Ability Test-9
  • Stroke Impact Scale (hand domain)
  • Somatosensory evoked potential

Secondary Outcome Measures:

  • Two-Minute Walk Test
  • Behavioral, neural activity and motor network connectivity levels, using functional MRI
  • *study will pay for SOC PT/OT if insurance is exhausted or subjects do not have insurance.

Mild Alzheimer’s Dementia Trial
This is an exciting trial looking at a medication that is thought to have an impact on amyloid accumulation thus possibly changing the progression of Alzheimer’s Dementia.


Mild Alzheimer’s Disease Dementia: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia.


Primary Outcome Measures:

  • Change from Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog-13) Score

Secondary Outcome Measures:

  • Change from Baseline in Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-iADL) Instrumental Items Score
  • Change from Baseline in Functional Activities Questionnaire (FAQ) Score
  • Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score
  • Change from Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score
  • Change in Clinical Dementia Rating (CDR) Global Score
  • Change from Baseline in Neuropsychiatric Inventory (NPI) Score
  • Change from Baseline on the Mini-Mental State Examination (MMSE)
  • Change from Baseline in Concentration of Cerebrospinal fluid (CSF) Biomarker Aβ1-42
  • Change from Baseline in Concentration of CSF Biomarker Aβ1-40
  • Change from Baseline in CSF Biomarker Total Tau
  • Change from Baseline in CSF Biomarker Phosphorylated Tau Change from Baseline in Brain Amyloid Burden using Florbetapir Amyloid Scan
  • Change from Baseline in Regional Cerebral Blood Flow (rCBF) using Florbetapir Perfusion Scan
  • Change from Baseline in Whole Brain Volume
  • Population Pharmacokinetics (PK): Apparent Oral Clearance of LY3314814
  • Population PK: Central Volume of Distribution of LY3314814

Relapsing Remitting MS Plegridy Observational Program
This is a study of patients who are on Plegridy. It is a long term observational study to better qualify and quantify the effectiveness and safety of this medication.

Relapsing Remitting MS Plegridy Observational Program (POP): Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program


Primary Outcome Measures:

  • Safety as measured by the incidence proportion of SAEs
  • Safety as measured by the incidence rate of SAEs
  • Clinical no evidence of disease activity (NEDA) as measured by the proportion of participants with no relapses
  • Clinical NEDA as measured by the proportion of participants with no disability progression

Secondary Outcome Measures:

  • Prescription and utilization patterns as measured by prescribed dosing frequency
  • Prescription and utilization patterns as measured by duration of Plegridy use
  • Prescription and utilization patterns as measured by the primary reason for discontinuation of Plegridy
  • Relapse activity as measured by annualized relapse rate (ARR)
  • Relapse activity as measured by time to first relapse
  • Relapse activity as measured by the proportion of participants with relapse
  • Relapse activity as measured by the distribution of the number of relapses
  • Disability progression as measured by the proportion of participants with sustained progression for at least six months

For questions, Inclusion/Exclusion criteria or additional information
please contact our Research Team:

1 (480) 566-9090